Search

Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children’s Medical Center Research Institute at UT Southwestern published in Cell.

A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyceride production and fatty acid synthesis in liver cells, UT Southwestern Medical Center researchers show in a new study.

About 1 in 11 people in the U.S. experience urinary stone disease – more commonly known as kidney stones – according to the National Institute of Diabetes and Digestive and Kidney Diseases. Increasing fluid intake has long been recommended to decrease the risk of recurrence in those who develop this painful condition. However, studies have shown that maintaining high fluid intake can be difficult.

Increased stiffness of the intestines, spurred by chronic inflammation, may encourage the development and progression of early-onset colorectal cancer (CRC), a study co-led by UT Southwestern Medical Center researchers suggests.

In localized non-small cell lung cancer (NSCLC), a tumor’s ability to use carbon from glucose to feed the tricarboxylic acid (TCA) cycle predicts cancer spread beyond the lung, months to years before metastases are clinically apparent. According to this new research from Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Cancer Discovery, tumors with this metabolic activity result in early patient death.

Stories published in 2026 about UT Southwestern Medical Center.

When activated in ovarian cancer cells, the receptor for the body’s primary stress hormone alters the tumor environment in ways that blunt immune response, according to new research led by UT Southwestern Medical Center.

Read past stories about the extraordinary work being done and the passionate people behind it.

Read past stories about the extraordinary work being done and the passionate people behind it.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).